Why Autolus And Cerus Traded Higher Today

Autolus Therapeutics (NASDAQ: AUTL) shares are trading higher on Monday after the company announced the publication of its new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine.

Autolus Therapeutics PLC is a biopharmaceutical company. It's engaged in the development of next-generation programmed T cell therapies for the treatment of cancer.

Autolus Therapeutics shares were trading up 6.70% at $10.25 at the time of publication on Monday. The stock has a 52-week high of $17.19 and a 52-week low of $3.

Cerus (NASDAQ: CERS) shares were trading higher after the company announced that the FDA approved its INTERCEPT blood system for cryoprecipitation.

Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites.

Cerus shares traded higher but were down 0.46% at $6.55 at the time of publication on Monday. The stock has a 52-week high of $7.94 and a 52-week low of $2.71.